Revenue
2022
2023
2024
2025
Galectin Therapeutics Inc (GALT)
Price$4.61Cached quote
Net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2011
2012
2013
2014
2015
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | — |
| Research & development | $14.3M | $36.6M | $32.1M | $31.7M | $23.8M | $18.0M | $7.5M | $6.5M | $11.7M | $15.3M | $13.1M | $8.4M | $5.7M | $4.5M | $3.6M | $1.1M |
| Operating expenses | $20.1M | $42.4M | $38.1M | $38.4M | $30.2M | $23.4M | $13.4M | $13.6M | $16.2M | $21.5M | $20.1M | $15.4M | $12.1M | $9.9M | $10.4M | $4.9M |
| Operating income | −$20.1M | −$42.4M | −$38.1M | −$38.4M | −$30.2M | −$23.4M | −$13.4M | −$13.6M | −$16.2M | −$21.5M | −$20.1M | −$15.4M | −$12.1M | −$9.9M | −$10.4M | −$4.9M |
| EBITDA | −$23.5M | −$42.4M | −$38.1M | −$38.4M | −$30.2M | −$23.4M | −$13.4M | −$13.6M | −$16.2M | −$21.5M | −$20.1M | −$15.4M | −$12.1M | −$9.9M | −$10.4M | −$4.9M |
| Net income | −$30.8M | −$47.0M | −$41.1M | −$38.8M | −$30.5M | −$23.5M | −$13.3M | −$13.9M | −$16.2M | −$21.4M | −$20.0M | −$15.8M | −$12.1M | −$9.7M | −$10.9M | −$5.6M |
| Basic EPSper basic share | -$0.48 | -$0.76 | -$0.74 | -$0.65 | -$0.52 | -$0.41 | -$0.39 | -$0.38 | -$0.49 | -$0.76 | -$0.88 | -$0.78 | -$1.30 | -$0.72 | -$1.06 | -$0.93 |
| Diluted EPSper diluted share | -$0.48 | -$0.76 | -$0.74 | -$0.65 | -$0.52 | -$0.41 | -$0.39 | -$0.38 | -$0.49 | -$0.76 | -$0.88 | -$0.78 | -$1.30 | -$0.72 | -$1.06 | -$0.93 |
Owners
Reported shareholders
≈15.62%of listed shares
Uihlein Richard E10.36M shares · Jan 16, 2026
View holders
| Holder | % owned |
|---|---|
Uihlein Richard E | ≈15.62%10.36M shares |
CZIRR JAMES C / 10X Fund, L.P. / 10X Capital Management, LLC | ≈8.47%5.61M shares |
BlackRock, Inc. | 4.51%2.99M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.27%2.17M shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.97%1.31M shares |
OSAIC HOLDINGS, INC. | 1.82%1.2M shares |
MARSHALL WACE, LLP | 1.25%831.01K shares |
Wealthspire Advisors, LLC | 1.09%721.79K shares |
STATE STREET CORP | 0.86%567.78K shares |
COMMONWEALTH EQUITY SERVICES, LLC | 0.61%407.11K shares |
NORTHERN TRUST CORP | 0.58%386.55K shares |
VANGUARD FIDUCIARY TRUST CO | 0.55%366.48K shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 0.49%327.77K shares |
TWO SIGMA INVESTMENTS, LP | 0.48%318.25K shares |
LPL Financial LLC | 0.43%285.38K shares |
Cambridge Investment Research Advisors, Inc. | 0.39%261.3K shares |
Sovran Advisors, LLC | 0.39%258K shares |
Geneos Wealth Management Inc. | 0.36%240.43K shares |
UBS Group AG | 0.33%219.32K shares |
RETIREMENT GUYS FORMULA LLC | 0.32%211.05K shares |
Percentages use 66.31M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 29, 2026Form 4 · 10b5-1 | Shlevin Harold H.Director | SellCommon Stock | 22.3K | $5.04 | $112.2K | 6.5K |
| Jun 29, 2026Form 4 · 10b5-1 | Jamil KhurramChief Medical Officer | SellCommon Stock | 47.5K | $5.04 | $239.2K | 0 |
| Jun 26, 2026Form 4 · 10b5-1 | Shlevin Harold H.Director | SellCommon Stock | 7.7K | $5.00 | $38.7K | 6.5K |
| Jun 26, 2026Form 4 · 10b5-1 | Jamil KhurramChief Medical Officer | SellCommon Stock | 2.5K | $5.00 | $12.7K | 0 |
| Jun 26, 2026Form 4 · 10b5-1 | Jamil KhurramChief Medical Officer | SellCommon Stock | 2.0K | $5.00 | $10.2K | 0 |